Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ivosidenib + nivolumab
- Development stage
- Unknown
- Lead developer
- Agios Pharmaceuticals
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Oral, Intravenous
01
Overview
Ivosidenib is a small molecule inhibitor of mutant isocitrate dehydrogenase 1 (IDH1), developed to target cancers with IDH1 mutations. By inhibiting the mutant IDH1 enzyme, it reduces levels of the oncometabolite D-2-hydroxyglutarate, restoring normal cell differentiation and slowing tumor growth. Nivolumab is a monoclonal antibody that targets programmed death receptor 1 (PD-1), acting as an immune checkpoint inhibitor to enhance T-cell mediated anti-tumor responses. The combination of these two drugs is being investigated for synergistic effects in treating IDH1-mutant glioma and other solid tumors, leveraging both targeted therapy and immunotherapy mechanisms[1][3][4][5][6].
- Other names
- ivosidenib + nivolumab
02
Targets
IDH1 (Isocitrate dehydrogenase [NADP] cytoplasmic)PDCD1 (Programmed cell death protein 1 receptor)
Beyond the preview
Go deeper on ivosidenib + nivolumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ivosidenib + nivolumab.